Read this topic

Why does one antidepressant class work through serotonin and another through dopamine? The answer traces back to a single gene family, SLC6, whose members build the reuptake transporters that decide which neurotransmitterA chemical messenger that nerve cells release to signal to the next cell.Read more → a drug can target. The same family connects to psychiatric genetics more broadly, because inherited variation in these genes — and in the monoamine oxidase (MAOMonoamine oxidase, an enzyme that breaks down mood-related brain chemicals.Read more →) enzyme genes that break the transmitters down — shapes both illness risk and how a person responds to treatment.

The SLC6 gene family encodes sodium-dependent transporter proteins that pump released neurotransmitterA chemical messenger that nerve cells release to signal to the next cell.Read more → back into the presynaptic neuron, ending its action at the synapseThe tiny gap between two nerve cells where a chemical signal passes from one to the other.Read more →. SLC6A4 encodes the serotonin transporter (SERT), the direct target of selective serotonin reuptake inhibitors (SSRIs). SLC6A2 encodes the noradrenaline transporter (NET), targeted by serotonin-noradrenaline reuptake inhibitors (SNRIs) and atomoxetine, and SLC6A3 encodes the dopamine transporter (DAT), the main target of stimulants such as methylphenidate. In contrast, the monoamine oxidase A (MAOA) gene, on the X chromosome, encodes an enzyme that breaks down serotonin, noradrenaline, and dopamine inside the neuron once they have already been taken back up — a breakdown step, not a reuptake step; a low-activity MAOA variant combined with childhood maltreatment is associated with increased risk of antisocial and aggressive behaviour in adulthood.

A vignette raises this concept when a question references a landmark gene-environment interaction study — childhood maltreatment plus a genetic variant predicting later antisocial behaviour (MAOA) or depression risk (SLC6A4/5-HTTLPR) — or when a question asks which gene encodes the molecular target of a named drug class.

• SLC6A4 (serotonin transporter, SERT) — reuptake gene; direct target of SSRIs.
• SLC6A2 (noradrenaline transporter, NET) — reuptake gene; target of SNRIs and atomoxetine.
• SLC6A3 (dopamine transporter, DAT) — reuptake gene; main target of stimulants such as methylphenidate.
• MAOA — breakdown-enzyme gene, not a transporter; degrades serotonin, noradrenaline and dopamine once already inside the neuron.
• SLC6A4's promoter (a DNA region controlling how much of the gene's product is made) carries 5-HTTLPR, a polymorphism (a common variation in DNA sequence) with a short allele (one version of the gene) and a long allele; MAOA carries its own separate promoter polymorphism, MAOA-uVNTR — the two are not the same variant.

A common trap is treating the short 5-HTTLPR allele alone as sufficient to cause depression; the evidence (Caspi et al., 2003) showed it acting through a gene-environment interaction with stressful life events, not alone — and later large meta-analyses did not consistently replicate that interaction, whereas the MAOA-by-maltreatment finding (Caspi et al., 2002) held up better. A second trap is confusing SLC6A4 (serotonin transporter) with MAOA (an enzyme, not a transporter). A third trap is assuming a low-activity MAOA variant alone predicts antisocial behaviour; the Caspi (2002) findings require childhood maltreatment as the second hit.

Step 1, identify whether the question is about reuptake (SLC6 family) or breakdown (MAOA/MAOB). Step 2: match the specific gene to its transmitter — SLC6A4 (serotonin), SLC6A2 (noradrenaline), SLC6A3 (dopamine). Step 3: if a gene-environment interaction is described, remember the genetic variant alone is not the whole story — an environmental exposure is required.